Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seagen

- PMLiVE

Pfizer’s RA drug tofacitinib tops methotrexate in phase III

Trial results back drug as major new treatment in rheumatoid arthritis

- PMLiVE

Sanofi taps Oncodesign for kinase inhibitor platform

French firms form €130m alliance

- PMLiVE

Finalists decided in UK cancer awards

QiC Excellence in Oncology aims to recognise good practice in cancer care throughout UK

Pfizer forms branded generics sales alliance in China

Forms joint venture with local company Hisun

- PMLiVE

Merck KGaA acquires cancer drug from Symphogen

Will pay up to €495m for investigational metastatic colorectal cancer treatment

- PMLiVE

Pfizer’s Andrew Thomas takes up UK comms agency role

Joins London-based Red Door Communications as head of international

Roche - Basel

Roche says pipeline will balance cancer drug patent losses

Has 11 new molecular entities in late-stage portfolio and 11 line extensions

INC Research promotes Susan Akers-Smith to senior oncology role

She takes up the position of VP of early phase oncology development

Pfizer gets US approval for leukaemia drug Bosulif

FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

Astellas wins US approval for prostate cancer drug Xtandi

Pharma company and its partner Medivation gain FDA licence for type of late-stage prostate cancer

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links